"Pathalys Pharma Raises $105M in Series B Funding, Focuses on Clinical Trials and FDA Approval"

Pathalys Pharma raises $105M in Series B Funding

Pathalys Pharma (Linkedin), a biotechnology research company based in the United States, has secured $105 million in Series B funding. With a focus on patients with end-stage kidney disease and secondary hyperparathyroidism, Pathalys Pharma is seeking partnerships with healthcare providers and pharmaceutical companies to advance therapeutics in nephrology.

Funding Amount: $105 million

Industry: Biotechnology Research

Employee Count: 2-10

CEO: Neal Fowler (CEO Linkedin)

What Pathalys Pharma needs to buy: Pathalys Pharma is looking for partnerships with clinical trial service providers, commercialization support services, and research collaborations with institutions specializing in nephrology. Companies in these areas can support Pathalys Pharma in advancing their clinical trials, commercializing their therapeutics, and developing additional treatments for end-stage kidney disease.